Eli Lilly's Retatrutide Triggers 25% Weight Loss in Phase 3 Trial

The 80-week study tracked adults without diabetes, administering weekly doses of 4 mg, 9 mg, or 12 mg. Those on the 12 mg regimen shed 25 percent of their body weight, while the 4 mg group saw a 17.6 percent reduction. By comparison, the placebo cohort lost only 3.9 percent. A subset of participants monitored for 104 weeks reached an average weight loss of 29.9 percent, though researchers caution this data comes from a smaller extension group.

Beyond weight reduction, the drug showed impact on obesity-related comorbidities. Patients with knee osteoarthritis reported improved pain management, and those suffering from obstructive sleep apnea saw breathing disruptions drop by 32.1 episodes per hour. Unlike existing treatments that target one or two hormone pathways, retatrutide activates GLP-1, GIP, and glucagon receptors to suppress appetite and modulate energy expenditure.

Clinical success arrived with notable side effects. Gastrointestinal issues, primarily nausea, affected 42 percent of the 12 mg group. Roughly 11 percent of these participants discontinued treatment due to adverse events, more than double the 4.6 percent dropout rate observed in the placebo group. While these findings, published in The New England Journal of Medicine, are promising, the trial did not establish cardiovascular safety or provide a direct head-to-head comparison with competitors like semaglutide.